Lower prevalence of BK virus infection in African American renal transplant recipients: A prospective study

Transplantation

Volumn 93, Issue 3, 2012, Pages 291-296

  Sood, Puneet ^a   Senanayake, Shamila ^a   Sujeet, Kumar ^a   Medipalli, Radhika ^a   Saad, Ehab ^a   Vasudev, Brahm ^a   Bresnahan, Barbara A ^a   Johnson, Christopher P ^a   Hariharan, Sundaram ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

BK virus; Infection; Kidney; Transplantation

Indexed keywords

INTERLEUKIN 2; INTERLEUKIN 2R; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; TACROLIMUS; THYMOCYTE ANTIBODY; UNCLASSIFIED DRUG;

ACUTE GRAFT REJECTION; ADULT; AFRICAN AMERICAN; CAUCASIAN; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; FEMALE; GRAFT RECIPIENT; GRAFT REJECTION; HIGH RISK PATIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; POLYOMAVIRUS INFECTION; POSTOPERATIVE COMPLICATION; PREVALENCE; PRIORITY JOURNAL; RACE DIFFERENCE; REVIEW; RISK FACTOR; TREATMENT DURATION; URINARY TRACT INFECTION; VIREMIA; VIRURIA;

ADULT; AFRICAN AMERICANS; BK VIRUS; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; ISOANTIBODIES; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; POLYOMAVIRUS INFECTIONS; PREVALENCE; PROSPECTIVE STUDIES; RISK FACTORS; TUMOR VIRUS INFECTIONS;

EID: 84856459284     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e31823ec05a     Document Type: Review

References (20)

1. Lipshutz GS, Flechner SM, Govani MV, et al. BK nephropathy in kidney transplant recipients treated with a calcineurin inhibitor-free immunosuppression regimen. Am J Transplant 2004; 4: 2132.
2. Brennan DC, Agha I, Bohl DL, et al. Incidence of BK with tacrolimus versus cyclosporine and impact of preemptive immunosuppression reduction. Am J Transplant 2005; 5: 582.
3. Bressollette-Bodin C, Coste-Burel M, Hourmant M, et al.Aprospective longitudinal study of BK virus infection in 104 renal transplant recipients. Am J Transplant 2005; 5: 1926.
4. Hussain S, Bresnahan BA, Cohen EP, et al. Rapid kidney allograft failure in patients with polyoma virus nephritis with prior treatment with antilymphocyte agents. Clin Transplant 2002; 16: 43.
5. Hirsch HH, Brennan DC, Drachenberg CB, et al. Polyomavirusassociated nephropathy in renal transplantation: Interdisciplinary analyses and recommendations. Transplantation 2005; 79: 1277.
6. Trofe J, Hirsch HH, Ramos E. Polyomavirus-associated nephropathy: Update of clinical management in kidney transplant patients. Transpl Infect Dis 2006; 8: 76.
7. Hirsch HH, Steiger J. Polyomavirus BK. Lancet Infect Dis 2003; 3: 611.
8. Randhawa PS, Khaleel-Ur-Rehman K, Swalsky PA, et al.DNAsequencing of viral capsid protein VP-1 region in patients with BK virus interstitial nephritis. Transplantation 2002; 73: 1090.
9. Awadalla Y, Randhawa P, Ruppert K, et al. HLA mismatching increases the risk of BK virus nephropathy in renal transplant recipients. Am J Transplant 2004; 4: 1691.
10. Dharnidharka VR, Cherikh WS, Abbott KC. An OPTN analysis of national registry data on treatment of BK virus allograft nephropathy in the United States. Transplantation 2009; 87: 1019.
11. Caillard S, Borni C, Olagne J, et al. Risk factors of BK virus infection in the era of therapeutic drug monitoring.AmJ Transplant 2011; 11(suppl 2): 259.
12. Sood P, Hariharan S. BK Virus infection after renal transplantation. Dialysis Transpl 2011; 40: 102.
13. Bohl DL, Storch GA, Ryschkewitsch C, et al. Donor origin of BK virus in renal transplantation and role of HLA C7 in susceptibility to sustained BK viremia. Am J Transplant 2005; 5: 2213.
14. Vincenti F, Charpentier B, Vanrenterghem Y, et al. A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study).AmJ Transplant 2010; 10: 535.
15. Busque S, Leventhal J, Brennan DC, et al. Calcineurin-inhibitor-free immunosuppression based on the JAK inhibitor CP-690,550: A pilot study in de novo kidney allograft recipients. Am J Transplant 2009; 9: 1936.
16. Sokolich J, Schain D, Magliocca J, et al. BK viruria/viremia and ureteral stent placement in kidney transplant recipients. Am J Transplant 2011; 11(suppl 2): 259.
17. Siparsky NF, Kushnir LF, Gallichio MH, et al. Ureteral stents: A risk factor for polyoma viremia in kidney transplant recipients undergoing protocol screening. Am J Transplant 2011; 11(suppl 2): 257.
18. Hoffman NG, Cook L, Atienza EE, et al. Marked variability of BK virus load measurement using quantitative real-time PCR among commonly used assays. J Clin Microbiol 2008; 46: 2671.
19. Bonvoisin C, Weekers L, Xhignesse P, et al. Polyomavirus in renal transplantation: A hot problem. Transplantation 2008; 85(7 suppl): S42.
20. Saad ER, Bresnahan BA, Cohen EP, et al. Successful treatment of BK viremia using reduction in immunosuppression without antiviral therapy. Transplantation 2008; 85: 850.